Stock Details
GILD is Gilead Sciences, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 62.05$. Average daily volumn in 3 months 8.22M. Market cap 78.11B



Stock symbol : GILD. Exchange : NasdaqGS. Currency : USD
Lastest price : 62.28$. Total volume : 3.98M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Gilead Sciences, Inc. (GILD)
Last Price
62.28$
Change
-0.56
Volume
3.98M

Previous Close62.83
Open62.83
Day Range62.13-63.49
Bid62.18 x 900
Ask62.19 x 1.1k
Volume3.98M
Average Volume8.22M
Market Cap78.11B
Beta0.38
52 Week Range57.17-74.12
Trailing P/E17.40
Foward P/E9.85
Dividend (Yield %)4.65%
Ex-Dividend Date2022-06-14



Financial Details


According to Gilead Sciences, Inc.'s financial reports the company's revenue in 2021 were 27.3B an increase( +12.5%) over the years 2020 revenue that were of 24.69B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 123M( +4778.05%).


Loading ...



Organization

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of li... ver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market Cap:
78.11B
Revenue:
27.3B
Total Assets:
67.95B
Total Cash:
5.34B


News about "Gilead Sciences, Inc."

gilead-gild-resubmits-nda-for-hiv-inhibitor-to-the-fda-image

Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA

Source from : YAHOO!Finance - 13 hours ago

Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.See details»


gilead-leadership-organization-of-black-employees-globe-raised-the-juneteenth-flag-image

Gilead Leadership Organization of Black Employees (GLOBE) Raised the Juneteenth Flag

Source from : Yahoo Finance - 13 hours ago

About Gilead SciencesGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.See details»


gilead-asks-fda-again-to-approve-twice-a-year-hiv-fighting-drug-image

Gilead asks FDA again to approve twice-a-year HIV-fighting drug

Source from : The Business Journals - 1 days ago

Gilead Sciences Inc. is asking the Food and Drug Administration for the second time in a year to approve its experimental twice-a-year HIV-fighting drug lenacapavir. The FDA in February rejected the ...See details»


how-florida-clinics-made-millions-by-manipulating-gileads-free-hiv-drug-program-image

How Florida clinics made millions by manipulating Gilead's free HIV drug program

Source from : The Business Journals - 1 days ago

A Florida health clinic agreed to pay $33 million to Gilead Sciences Inc. for its parts in a scheme to fraudulently prescribe and distribute a Gilead HIV prevention drug through a program designed to ...See details»


gilead-kites-car-t-cell-therapy-yescarta-gets-eu-approval-to-treat-relapsed-or-refractory-fl-image

Gilead: Kite's CAR T-cell Therapy Yescarta Gets EU Approval To Treat Relapsed Or Refractory FL

Source from : Nasdaq - 16 hours ago

(GILD) announced Tuesday that its cell therapy company Kite's CAR T-cell therapy Yescarta (axicabtagene ciloleucel) received European marketing authorization from the European Commission to treat ...See details»


phase-iii-data-from-gileads-hepatitis-d-cure-and-madrigals-nash-hopeful-take-center-stage-at-ilc-image

Phase III data from Gileadโ€™s hepatitis D โ€˜cureโ€™ and Madrigalโ€™s NASH hopeful take center stage at ILC

Source from : BioWorld - 1 days ago

New data confirming that Gilead Sciences Inc.โ€™s Hepcludex (bulevirtide) effectively cures hepatitis delta virus (hepatitis D), one of the most severe viral infections of the liver, and favorable phase ...See details»


coastal-investment-advisors-inc-sells-193-shares-of-gilead-sciences-inc-nasdaqgild-image

Coastal Investment Advisors Inc. Sells 193 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Source from : Defense World - 2 days ago

Coastal Investment Advisors Inc. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 5.3% in the first quarter, HoldingsChannel reports. The firm owned 3,478 shares of ...See details»


gilead-sciences-inc-nasdaqgild-shares-sold-by-mcia-inc-image

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MCIA Inc

Source from : ETF Daily News - 6 days ago

MCIA Inc trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 7.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 24,153 shares of ...See details»


carnegie-capital-asset-management-llc-cuts-holdings-in-gilead-sciences-inc-nasdaqgild-image

Carnegie Capital Asset Management LLC Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Source from : ETF Daily News - 3 days ago

Carnegie Capital Asset Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 5.1% in the first quarter, according to the company in its most recent ...See details»


gilead-sciences-supports-kigali-declaration-for-neglected-tropical-diseases-image

Gilead Sciences supports Kigali Declaration for neglected tropical diseases

Source from : PMLiVE - 14 hours ago

1.7 billion people around the world are affected by tropical diseases, which are prevalent in tropical areas and mostly affect impoverished communities ...See details»


carnegie-capital-asset-management-llc-has-358000-position-in-gilead-sciences-inc-nasdaqgild-image

Carnegie Capital Asset Management LLC Has $358,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Source from : Defense World - 3 days ago

Carnegie Capital Asset Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 5.1% in the first quarter, HoldingsChannel.com reports. The fund owned 6,025 shares ...See details»


Gilead: Week 48 Findings Underscore Efficacy Of Bulevirtide For Treatment Of Chronic HDV

Source from : Nasdaq - 5 days ago

(GILD) reported week 48 results from the phase 3 trial evaluating Hepcludex or bulevirtide for the treatment of chronic hepatitis delta virus infection. The company said these data reinforce the ...See details»


gileads-social-justice-experience-helps-raise-awareness-of-the-black-journey-in-the-united-states-image

Gilead's Social Justice Experience Helps Raise Awareness of the Black Journey in the United States

Source from : CSR Wire - 1 days ago

The Social Justice Experience is a virtual, interactive platform that examines the Black American experience with a timeline of Black history in America dating back to 1619.See details»


Gilead Sciences, Inc. (GILD) CEO Dan O'Day Presents at Goldman Sachs Global Healthcare Conference (Transcript)

Source from : Seeking Alpha - 13 days ago

Goldman Sachs Global Healthcare Conference June 15, 2022 02:20 PM ET Company Participants Dan O'Day - Chairman & Chief Executive ...See details»